What's in BRACCO's pipeline?

BRACCO has 12 drugs in our index: 12 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with BRACCO's portfolio?

Top competitors by shared drug class: , GE HealthCare, Bayer, Fresenius Kabi, Guerbet.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bracco.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

BRACCO — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BRACCO pipeline: 12 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Guna-Geriatrics	BARIUM	marketed	Adrenocorticotropic Hormone [EPC]		Nephrology	2019-01-01
Multihance	GADOBENATE DIMEGLUMINE	marketed	gadobenate dimeglumine		Other	2004-01-01
Prohance	GADOTERIDOL	marketed	Paramagnetic Contrast Agent		Other	1992-01-01
Rubidium Chloride Rb 82	rubidium Rb-82 chloride	marketed			Hematology	1989-01-01
Choletec	TECHNETIUM TC 99M MEBROFENIN	marketed	Radioactive Diagnostic Agent		Urology	1987-01-01
Ametriodic Acid	IODAMIDE	marketed	iodamide		Hematology	1978-01-01
Sincalide	SINCALIDE	marketed	Cholecystokinin Analog [EPC]	Cholecystokinin receptor type A	Gastroenterology	1976-01-01
Ipodate	iopodic acid	marketed	iopodic acid		Other	1962-01-01
Cystografin Dilute	DIATRIZOATE MEGLUMINE	marketed	diatrizoate meglumine		Other	1955-01-01
Cholografin Meglumine	IODIPAMIDE SODIUM	marketed	Radiographic Contrast Agent		Gastroenterology	1954-01-01
Cholografin Meglumine	adipiodone	marketed	Radiographic Contrast Agent		Gastroenterology	1954-01-01
LUMENHANCE	MANGANESE CHLORIDE TETRAHYDRATE	marketed			Other

Therapeutic area mix

Other · 5
Gastroenterology · 3
Hematology · 2
Nephrology · 1
Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2038-04-20 — Sincalide · 11737983 · Formulation · US
2038-04-20 — Sincalide · 11318100 · Formulation · US
2038-04-20 — Sincalide · 11110063 · Formulation · US

Competitive overlap (companies sharing drug classes)

· 3 shared drug classes
GE HealthCare · 2 shared drug classes
Bayer · 1 shared drug class
Fresenius Kabi · 1 shared drug class
Guerbet · 1 shared drug class
Guna spa · 1 shared drug class
Lantheus Medcl · 1 shared drug class
Liebel-Flarsheim · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for BRACCO:

Cite this brief

Drug Landscape (2026). BRACCO — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bracco. Accessed 2026-06-10.